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Abstract
Our aim was to assess the evolution and the impact that blips, intermittent low-level viraemia and virological failure (VF) episodes have on
patients’ immune activation (IA) profiles during ritonavir-boosted darunavir monotherapy (mtDRV/rtv). A prospective cohort of human
immunodeficiency virus-1-infected patients who switched to mtDRV/rtv was followed for 2 years. Cellular IA was assessed according to
HLA-DR and CD38 expression in CD4+ and CD8+ T-cells and their na€ıve, effector memory and central memory subpopulations, and
systemic IA was evaluated according to sCD14 and D-dimer levels. Seventy-five patients from the MonDAR cohort were selected for this
substudy, and classified according to viral outcome as having continuous undetectable viraemia (n = 19), blips (n = 19), intermittent
viraemia (n = 21), and VF (n = 16). The IA profile was closely linked to viral behaviour. Patients on viral suppression for 24 months showed
a significant decrease in CD4+ and CD8+ T-cell activation and sCD14 and D-dimer levels. Patients with transient low-level viraemia episodes
(blips and intermittent viraemia) showed cellular and systemic IA similar to baseline values. In contrast, significant increases in T-cell
activation and sCD14 and D-dimer levels were observed in patients with VF. Baseline levels of HLA-DR+CD38+CD8+ T-cells of >6.4% were
independently associated with the emergence of VF. Therefore, mtDRV/rtv might be considered as a safe simplification strategy, on the basis
of the IA results, whenever viral replication is under medium-term and long-term control. Transient low-level viraemia episodes do not
affect patients’ IA status. Moreover, HLA-DR+CD38+CD8+ T-cell baseline levels should be considered when patients are switched to
mtDRV/rtv.
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Introduction
Persistent immune activation (IA) is a hallmark of chronic
human immunodeficiency virus (HIV) infection, even under
long-term suppressive combined antiretroviral therapy. Higher
levels of IA are associated with impaired CD4+ T-cell
reconstitution [1,2], higher mortality rates [3,4], and AIDS
and non-AIDS-defining illnesses [5,6]. On the other hand, an
increasing number of studies have demonstrated that ritona-
vir-boosted protease inhibitor monotherapy (mtPI/rtv), mainly
based on lopinavir and darunavir, might be considered as an
alternative strategy for treatment simplification in long-term
virologically suppressed HIV-1-infected patients, with similar
efficacy rates as triple therapy [7–17]. Nevertheless, important
concerns regarding the safety of this therapeutic option
remain, such as the increased incidence of blips and persistent
viraemia episodes [18]. This residual viraemia might potentially
induce a substantial increase in IA [19]; however, no studies of
mtPI/rtv have addressed this issue to date. In this study, we
assessed IA evolution throughout a period of darunavir/
ritonavir monotherapy (mtDRV/rtv), and particularly the
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influence that blip, intermittent viraemia and virological failure
(VF) episodes have on the IA profile of HIV-1-infected patients.
Materials and Methods
Patients and study design
The MonDAR study (Clinical Trials.gov identifier:
NCT01606722) prospectively enrolled all HIV-1-infected
patients who were started on an mtDRV/rtv (800/100 mg
once daily) simplification strategy at our outpatient clinic from
January 2010 to April 2011 if they had: (i) a plasma HIV RNA
level that was consistently <50 copies/mL for at least
6 months; and (ii) no resistance mutations that would confer
decreased susceptibility to darunavir according to the Inter-
national AIDS Society [20]. The study was conducted after
informed consent had been obtained, according to the
principles of the Declaration of Helsinki, and was approved
by the Committee for Ethics in Biomedical Research of
Andalucıa and the Spanish Agency for Medicines.
Patients with available samples at months 0, 6, 12, 18 and 24
were included in this IA substudy, and were classified into four
non-overlapping groups according to the following viral
outcome on mtDRV/rtv based on a median of 10 viral load
determinations per subject (interquartile range (IQR) 8–10):
(i) continuous undetectable viraemia (CUV), for patients on
viral suppression (<20 copies/mL) during the 24 months of the
follow-up; (ii) blips, defined as transitory episodes of HIV RNA
viral loads of >50 copies/mL, preceded and followed by a
plasma viral load of <50 copies/mL without changes in the
antiretroviral treatment; (iii) VF, defined as two consecutive
viral load measurements of >200 copies/mL; and (iv) intermit-
tent viraemia (IV), defined as episodes of detectable plasma
HIV RNA during the follow-up without meeting the blip or VF
criteria. Adherence was assessed by personal interview at each
patient visit, and by analysis of the hospital pharmacy records.
Follow-up and laboratory procedures
Patient assessments were performed at baseline, after the first
month on treatment, and every 3 months thereafter, including
biochemical and haematological profiles, CD4+ T-cell counts,
and plasma HIV-1 viraemia (COBAS AmpliPrep/COBAS Taq-
Man HIV-1 Test, version 2.0; Roche Diagnostic Systems,
Branchburg, NJ, USA), with a limit of detection of 20 copies/
mL.
Blood samples were collected in Vacutainer cell preparation
tubes (BD Biosciences, Madrid, Spain) at baseline and at each
clinical visit during the 24 months of follow-up. We analysed
samples from the CUV, IV and VF groups drawn at months 0,
6, 12, 18 and 24 of mtDRV/rtv treatment. Moreover, the IA
profile changes in patients with blips and VF episodes were
intensively analysed before each episode, at the moment of the
viral rebound, and after each episode.
Peripheral blood mononuclear cell samples were stained
with the following antibodies: aCD3-V450 (clone UCHT1),
aCD4-APC-H7 (clone RPA-T4), aCD8-V500 (clone RPA-T8),
aCD45RA-FITC (clone HI-100), aCD45RO-PE (clone
UCHL1), aCCR7-PerCP-Cy5.5 (clone 150503), aCD38-APC
(clone HIT-2), and aHLA-DR-PE-Cy7 (clone G46.6).
Unstained controls and the following control antibodies were
used: aCD4-APC-H7, aCD38-APC, aCD45RO-PE, and
aHLA-DR-PE-Cy7. All of the antibodies were from BD
Biosciences. Briefly, peripheral blood mononuclear cell sam-
ples were lysed with 100 lL of FACS lysing solution (BD
Biosciences) to remove any remaining red blood cells. Then,
the cells were washed with phosphate-buffered saline, stained
for 30 min in the dark, washed again with phosphate-buffered
saline, and resuspended in 1% paraformaldehyde. The cells
were acquired with an LSR Fortessa flow cytometer (BD
Biosciences), and at least 30 000 CD3+ T-cells were analysed
with FACSDiva software (BD Biosciences). IA was studied
according to the single and double expression of HLA-DR and
CD38 in T-cell subsets, grouped as na€ıve (CD45RA
+CD45RO), effector memory (CD45RACD45RO+CCR7+)
and central memory (TCM; CD45RA
CD45RO+CCR7), as
previously described [21,22].
Moreover, sCD14 levels (Human sCD14 Quantikine ELISA;
R&D Systems, Abingdon, UK) and plasma D-dimer levels
(Human D-Dimer ELISA Kit; CUSABIO, Wuhan, China) were
quantified by the use of ELISA-based assays, following the
manufacturer’s recommendations, at baseline and after
24 months of mtDRV/rtv.
Statistical analysis
Results were expressed as median and IQR for continuous
variables, and percentages for categorical variables. The Mann–
Whitney U-test and Kruskal–Wallis H-test were used to
compare the medians between the different groups, and the
Wilcoxon and Freidman tests were used to compare patients
within the same group. Correlations between age, time on
highly active antiretroviral therapy or duration of viral sup-
pression and IA markers (HLA-DR/CD38 expression in both
CD4+ and CD8+ T-cells) were assessed with the Pearson
correlation test. Receiver operating characteristic curves were
constructed to discriminate between the different cut-off values
of the IA markers at baseline, and their ability to predict VF on
mtDRV/rtv, and areas under the curve of >0.65 were consid-
ered for further analysis. The cumulative incidence of VF during
mtDRV/rtv treatment by month 24 as a function of the baseline
levels of the IA markers was assessed with Kaplan–Meier
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analysis and long-rank tests. A Cox regression analysis was
performed to identify potential predictive factors for VF during
mtDRV/rtv treatment. The variables associated with VF in the
bivariate analysis were introduced into the model, and hazard
ratios (HRs) were obtained. Potential time-dependent interac-
tions were studied for each variable before their introduction
into the model. The differences were considered to be
statistically significant at p <0.05. The statistical analyses were
performed with SPSS software (v. 19.0; SPSS, Chicago, IL, USA),
and the graphs were generated with GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA).
Results
Seventy-five subjects from a total of 150 Caucasian patients
enrolled in the MonDAR study were selected on the basis of
sample availability, and categorized as having CUV (n = 19),
blips (n = 19), IV (n = 21), and VF (n = 16). The baseline
characteristics were similar among the different groups,
especially for factors that may potentially influence IA status,
such as age, duration of viral suppression, or hepatitis C virus
co-infection (Table 1). The mean adherence throughout the
follow-up period was 100% for subjects with CUV (IQR 96–
100%), 100% for those with blips (IQR 93.5–100%), 100% for
those with IV (IQR 96.5–100%), and 93% for those with VF
(IQR 80–100%, p 0.033). No correlations were found
between age or type of previous regimen and any of the IA
markers studied at baseline. Only a weak correlation between
time on highly active antiretroviral therapy and baseline levels
of HLA-DR+CD38+CD8+ T-cells was found (r2 = 0.138,
p 0.008).
CD4+ and CD8+ T-cell activation during 24 months on
mtDRV/rtv
Although no significant differences were found in the expres-
sion of HLA-DR+, CD38+ or HLA-DR+/CD38+ on CD4+ and
CD8+ T-cells at baseline among the different groups (Table 1),
their evolution was heterogeneous. Thus, CUV patients
showed a decrease in cellular IA markers after 24 months
on mtDRV/rtv in both CD4+ T-cells (HLA-DR+CD38+ base-
line, 4.6% vs. month 24, 4.2%, p 0.022; Fig. 1a) and CD8+
T-cells (HLA-DR+CD38+, baseline, 5.0% vs. month 24, 4.4%,
p 0.003; Fig. 1d, Table S1), whereas these values showed no
significant changes in the IV group (Fig. 1b,e). By contrast, in
the VF group, these IA markers showed a significant increase
after 24 months of follow-up (CD4+HLA-DR+CD38+ baseline,
6.1% vs. month 24, 7.1%, p 0.022; Fig. 1c;
CD8+HLA-DR+CD38+, baseline, 7.4% vs. month 24, 9.4%,
p 0.068; Fig. 1f), even when all these patients had regained
virological control at a median of 10 weeks previously (range:
3–15 months) through re-introduction of the previous nucle-
oside analogue backbone (n = 7) or continuation of mtDRV/
rtv treatment after adherence counselling (n = 9) (Table 2).
These changes were mostly attributable to the TCM subpop-
ulations in both CD4+ and CD8+ T-cells (Tables S2 and S3).
Impact of blips and VF on the T-cell activation profile
A total of 31 blip episodes from 19 patients on mtDRV/rtv
were intensively analysed before, during and after the viraemic
TABLE 1. Patients’ baseline characteristics
CUV (n = 19) B (n = 19) IV (n = 21) VF (n = 16) p-valuea
Age (years), median (IQR) 47 (42–50) 47 (39–50) 44 (39–50) 46 (42–49) 0.852
Sex (male), n (%) 14 (73.7) 13 (68.4) 19 (90.5) 10 (62.5) 0.147
Chronic hepatitis C, n (%) 4 (21.1) 6 (31.6) 4 (19.0) 4 (25.0) 0.286
Time on HAART (months),
median (IQR)
117.0 (86.0–160.0) 82.0 (42.0–136.0) 100.0 (66.0–130.0) 83.5 (47.3–121.8) 0.432
Time on viral suppression
(months), median (IQR)
68.0 (40.0–97.0) 39.0 (32.0–97.0) 51.0 (34.5–84.5) 42.5 (16.0–67.8) 0.507
CD4+ T-cell counts (cell/lL),
median (IQR)
545 (388–713) 592 (502–856) 560 (327–897) 598 (435–784) 0.597
Nadir CD4+ T-cell counts
(cell/lL), median (IQR)
163 (32–224) 143 (67–214) 177 (94–264) 125 (37–222) 0.310
Zenit VL (log copies/mL),
median (IQR)
5.1 (4.7–5.7) 5.2 (4.9–5.9) 5.2 (4.8–5.4) 5.2 (5.0–5.5) 0.574
Blips in the previous 12 months, n (%) 2 (10.5) 6 (31.6) 8 (38.1) 5 (31.3) 0.127
CD4+ T-cells
HLA-DR+ (%), median (IQR) 4.4 (3.5–5.1) 2.2 (1.4–5.3) 2.8 (2.2–3.9) 2.8 (2.0–3.6) 0.185
CD38+ (%), median (IQR) 31.1 (22.4–49.0) 27.4 (18.9–55.0) 34.6 (29.2–44.4) 38.6 (30.2–55.2) 0.456
HLA-DR+CD38+ (%), median (IQR) 4.6 (3.9–7.0) 3.2 (2.3–4.9) 5.5 (2.7–7.0) 6.1 (4.5–7.2) 0.389
CD8+ T-cells
HLA-DR+ (%), median (IQR) 6.7 (3.1–4.7) 3.2 (2.5–5.2) 3.0 (1.5–4.9) 3.5 (1.5–5.1) 0.605
CD38+ (%), median (IQR) 15.7 (9.7–28.9) 12.5 (7.9–18.9) 16.8 (11.3–23.5) 21.4 (13.4–35.2) 0.329
HLA-DR+CD38+ (%), median (IQR) 5.0 (4.2–8.8) 4.6 (2.0–6.1) 5.6 (4.0–7.8) 7.4 (6.3–10.6) 0.090
B, blips; CUV, continuous undetectable viraemia; HAART, highly active antiretroviral therapy; IQR, interquartile range; IV, intermittent viraemia; VF, virological failure; VL, viral load.
ap-value between groups: Kruskal–Wallis H-test.
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episodes. No major changes were observed in either CD4+
T-cells (prior to blip, 3.2% vs. blip, 2.9% vs. after blip, 3.3%,
p 0.312; Table S4) or CD8+ T-cells (prior to blip, 4.6% vs. blip,
4.4% vs. after blip, 2.9%, p 0.368; Table S4) according to the
expression of HLA-DR/CD38.
By contrast, VF episodes (n = 16) induced significant
increases in the expression of CD38 (38.5% vs. 51.3%,
p 0.039) and HLA-DR/CD38 (5.4% vs. 6.8%, p 0.045) on
CD4+ T-cells as compared with the baseline and the median
values during the periods with undetectable viral load. These
changes were mainly attributable to the contribution of TCM
CD4+ T-cells. Just at VF, similar trends were observed for
CD8+ T-cells (HLA-DR, 4.4% vs. 6.1%, p 0.10; CD38, 15.9% vs.
19.8%, p 0.807; and HLA-DR/CD38, 7.3% vs. 8.5%, p 0.917),
(a) (b) (c)
(d) (e) (f)
FIG. 1. Immune activation in CD4+ T-cell compartment evolution during 96 weeks of ritonavir-boosted darunavir monotherapy (mtDRV/rtv)
treatment. CUV, continuous undetectable viraemia; IV, intermittent viraemia; VF, virological failure.
TABLE 2. Immune activation of T-cells in the different viraemic groups at baseline and month 24 of ritonavir-boosted darunavir
monotherapy
CUV IV VF
Basal Month 24 p-valuea Basal Month 24 p-valuea Basal Month 24 p-valuea
CD4+ T-cells
HLA-DR+ (%) 4.4 (3.5–5.1) 3.7 (1.9–6.0) 0.600 2.8 (2.2–3.9) 2.5 (1.9–3.1) 0.683 2.8 (2.0–3.6) 2.4 (0.9–4.7) 0.959
CD38+ (%) 31.1 (22.4–49.0) 28.8 (20.8–33.7) 0.035 34.6 (29.2–44.4) 42.4 (33.4–47.8) 0.609 38.6 (30.2–55.2) 51.1 (45.1–63.1) 0.047
HLA-DR+CD38+ (%) 4.6 (3.9–7.0) 4.2 (3.3–5.1) 0.022 5.5 (2.7–7.0) 4.0 (3.4–4.7) 0.078 6.1 (4.5–7.2) 7.1 (4.8–13.7) 0.022
CD8+ T-cells
HLA-DR+ (%) 6.7 (3.1–4.7) 2.5 (1.2–4.5) 0.008 3.0 (1.5–4.9) 2.1 (1.0–2.7) 0.147 3.5 (1.5–5.1) 5.4 (3.0–9.6) 0.008
CD38+ (%) 15.7 (9.7–28.9) 11.8 (7.4–17.4) 0.003 16.8 (11.3–23.5) 23.1 (15.4–39.3) 0.111 21.4 (13.4–35.2) 35.7 (16.9–50.2) 0.285
HLA-DR+CD38+ (%) 5.0 (4.2–8.8) 4.4 (3.3–5.6) 0.003 5.6 (4.0–7.8) 4.4 (3.6–6.5) 0.280 7.4 (6.3–10.6) 9.4 (5.6–11.2) 0.068
CUV, continuous undetectable viraemia; IV, intermittent viraemia; VF, virological failure. Values are expressed as median and interquartile range.
ap-value between groups: Wilcoxon test.
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although without reaching statistical significance (Table S5),
but being more evident in the later determinations at
month 24.
sCD14 and D-dimer levels during mtDRV/rtv treatment
No baseline differences were found in sCD14 and D-dimer
levels among the groups with different virological outcomes.
However, sCD14 levels decreased significantly in the CUV
group (22.6 lg/mL, IQR 67.7 to 1.0 lg/mL), remained
stable in the blip (2.1 lg/mL, IQR 24.9 to 8.1 lg/mL) and
IV groups (1.5 lg/mL, IQR 17.9 to 15.6), but increased
significantly in the VF group (31.5 lg/mL, IQR 7–69.7 lg/mL,
p 0.027; Fig. 2a). Moreover, whereas D-dimer levels
decreased in most of the groups after 24 months of treatment
(CUV, 14.06 ng/mL, IQR 57.26 to 3.33 ng/mL; IV,
7.54 ng/mL, IQR 36.03 to 5.37 ng/mL; blips, 5.20 ng/
mL, IQR 39.72 to 4.11 ng/mL), these levels increased
significantly in the VF group (6.01 ng/mL, IQR 0.17 to
21.75 ng/mL, p 0.001; Fig. 2b).
Influence of IA on VF during mtDRV/rtv treatment
Comparison of the clinical and immunological baseline char-
acteristics of patients with and without VF while on mtDRV/rtv
showed that only the coexpression of HLA-DR and CD38 on
CD8+ T-cells was significantly higher in patients who experi-
enced VF while on mtDRV/rtv (7.4% vs. 5.6%, p 0.030;
Table S6). After a receiver operating characteristic analysis,
the best cut-off value for HLA-DR+CD38+CD8+ T-cells
associated with VF during mtDRV/rtv treatment was 6.4%
(AUC 0.699; 95% CI 0.531–0.876), with a sensitivity and
specificity of 71.4% and 72.2%, respectively. In addition,
positive and negative predictive values were calculated, and
were 71.4% and 86.7%, respectively. The survival analysis
indicated a cumulative probability of VF during mtDRV/rtv
treatment by month 24 of 51.8% in patients with baseline
levels of HLA-DR+CD38+CD8+ T-cells of >6.4%, whereas only
14% of patients with lower levels failed treatment (log-rank
p 0.006; Fig. S1). A Cox regression model showed that the
only variables independently associated with VF during
mtDRV/rtv treatment were a baseline level of
HLA-DR+CD38+CD8+ T-cells of >6.4% (HR 5.99;
95% CI 1.52–23.54; p 0.010) and adherence to treatment of
<95% (HR 4.30; 95% CI 1.36–13.64; p 0.013; Table 3).
Discussion
Simplification therapies based on mtPI/rtv have been associ-
ated with higher rates of intermittent episodes of low-level
viraemia than those seen with triple therapy [18]. Neverthe-
less, the real consequences of these episodes need to be fully
assessed, because those reported have only focused on the
risk of subsequent VF [23–25].
Our results show that the IA profile was closely linked to
viral outcome during mtDRV/rtv treatment. Thus, patients
with undetectable viraemia throughout the 24 months of
follow-up showed significant decreases both in the activation
markers of CD4+ and CD8+ T-cells and in sCD14 and D-dimer
levels. Likewise, the blip episodes had no effects on either
CD4+ T-cells, CD8+ T-cells, or soluble markers of IA, most
likely because of the transitory and low level of viraemia. In
contrast, significant increases in both CD4+ and CD8+ T-cell
activation, sCD14 levels and D-dimer levels were observed in
those patients who experienced VF, these being evident after a
median of 10 weeks after virological control had been
regained. This is consistent with the theory originally proposed
by Karlsson et al. [26], who suggested that increases in IA of
T-cells would not be observed without a simultaneous
increase in viral replication. Patients with transient low-level
viraemia were halfway between the CUV and VF groups. This
is particularly relevant, as previous studies have pointed out
that these transient low-level viraemia episodes increase the IA
profile of CD8+ T-cells [27]; herein, our results showed that
IA status was not modified in either CD4+ or CD8+ T-cells.
Even though the cellular IA profile remained stable throughout
the follow-up, it did not show the decrease seen in the CUV
(a) (b)
FIG. 2. Evolution of sCD14 (a) and D-dimer (b) levels as a function of virological outcome during 24 months of ritonavir-boosted darunavir
monotherapy. CUV, continuous undetectable viraemia; IV, intermittent viraemia; VF, virological failure.
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patients. Therefore, on the basis of the IA results, mtDRV/rtv
is a safe simplification strategy, and blip episodes should not be
a cause for alarm whenever viral replication is under control in
the medium and long term. One limitation of our study might
be the selection of the patients, as only those with available
samples at all of the clinical visits were included. However, this
criterion supposes blind selection of the patients, uninfluenced
by any other parameter or baseline characteristic that would
change the study results, as similar numbers of patients were
included in each study group.
To the best of our knowledge, no previous study has
focused on the value of baseline IA for predicting VF in patients
on mtPI/rtv. With triple-therapy regimens, several studies have
reported that IA markers could be considered as prognostic
factors for high levels of HIV-1 viraemia [28] and disease
progression [4,29,30]. Here, we have also observed that
coexpression of HLA-DR and CD38 by CD8+ T-cells is
associated with VF during mtDRV/rtv treatment. This factor
was independently associated with VF, together with adher-
ence, whereas other factors, such as nadir CD4+ T-cell count
or time on viral suppression, which are traditionally associ-
ated with worse treatment outcomes, had no influence on
VF in our cohort. The cut-off value suggested for
HLA-DR+CD38+CD8+ T-cells might be relevant for the
enrolment of patients in future simplification strategies
although larger cohort studies are needed to support this
value.
To summarize, mtDRV/rtv is a safe simplification strategy
according to the IA results, and blip episodes should not be
cause for alarm whenever replication is under medium-term
and long-term control. Higher baseline levels of
HLA-DR+CD38+CD8+ T-cells were independently associated
with the emergence of VF.
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